Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Adaptimmune Therapeutics PLC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
9.87
14.2
37.8
59.5
1.12
3.96
6.15
27.1
60.3
178
Cost of revenue
0.07
Gross profit
178
Research and development
24.1
63.8
87.4
98.3
97.5
91.6
111
128
127
149
Selling, general and administrative
63.4
73.5
87.3
General and administrative
10.4
23.2
31.1
43.6
43.4
45.8
57.3
63.4
73.5
Operating income
-24.6
-72.8
-80.7
-82.4
-140
-133
-162
-164
-140
-68.8
Interest expense
3.35
Interest income
0.5
1.11
2.23
2.85
2.77
Other non-operating income
2.32
1
8.74
-15.5
0.08
1.16
3.85
-0.54
-0.81
-1.73
Pre-tax income
-21.8
-70.7
-69.7
-95
-137
-130
-157
-163
-113
-67.2
Income tax
0.24
0.89
0.45
0.5
0.24
0.16
0.79
2.5
1.34
3.58
Net income
-22.1
-71.6
-70.1
-95.5
-137
-130
-158
-165
-114
-70.8
EBITDA
-23.9
-69.7
-75.6
-75.2
-133
-127
-157
-159
-130
-57.9
EPS, basic
-0.17
-0.17
-0.13
-0.16
-0.22
-0.15
-0.17
-0.17
-0.09
-0.05
EPS, diluted
-0.17
-0.17
-0.13
-0.16
-0.22
-0.15
-0.17
-0.17
-0.09
-0.05
Shares, basic (weighted)
215
425
528
584
630
855
935
967
1,206
1,514
Shares, diluted (weighted)
215
425
528
584
630
855
935
967
1,206
1,514
Balance sheet
FY2016
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
229
159
84
68.4
50.4
56.9
150
108
144
91.1
Short-term investments
124
137
39.1
311
220
96.6
2.95
60.5
Receivables
0
1.48
0.21
0.19
0.14
0.75
7.44
0.82
1.45
Inventory
7.32
Other current assets
10.7
0.98
0.38
0.44
1.81
0.44
2.08
1.93
2.41
3.17
Total current assets
295
199
230
231
120
398
415
255
208
188
Property, plant and equipment
5.39
27.9
40.7
36.1
31.1
27.8
30.5
53.5
50.9
31.3
Lease right-of-use assets
20.8
18.9
20.9
18
20.8
19.9
Intangible assets
0.18
1.27
1.34
1.47
2.2
1.73
1
0.44
0.33
3.88
Other non-current assets
0.63
Total assets
301
235
281
277
182
451
470
329
283
246
Accounts payable
1.98
11.4
8.38
4.08
6.36
6.39
8.11
4.75
8.13
8.69
Accrued liabilities
0.25
4.54
6.59
20.4
23.4
27.1
29.9
31.2
30.3
32.9
Deferred revenue
20.9
11.4
38.7
2.13
2.83
22.2
23.5
29
12.3
Total current liabilities
26.8
40.3
74.3
24.4
34.3
39.1
62.5
64.5
72.8
64.5
Long-term debt
50.2
Lease liabilities
23
20.9
23.1
20.3
19.9
19.3
Other non-current liabilities
3.14
3.85
5.41
0.6
0.64
0.67
1.3
1.4
4.27
Total liabilities
41.7
68.4
78.2
29.9
57.9
110
264
247
243
234
Total debt
54.3
Paid-in capital
329
341
455
574
586
936
960
991
1,065
1,106
Retained earnings
-66.9
-161
-232
-318
-456
-586
-744
-909
-1,023
-1,094
Other comprehensive income
-3.56
-14.2
-21.6
-9.76
-7.26
-10
-11.1
-0.88
-3.75
-1.9
Shareholders' equity
259
166
203
247
124
341
206
81.9
39.5
11.8
Total equity
259
166
203
247
124
341
206
81.9
39.5
11.8
Total liabilities and equity
301
235
281
277
182
451
470
329
283
246
Shares outstanding
425
425
562
627
631
929
929
987
1,363
1,536
Cash flow statement
FY2016
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-22.1
-71.6
-70.1
-95.5
-137
-130
-158
-165
-114
-70.8
Depreciation and amortization
0.71
3.13
5.03
7.19
7.17
6.63
5.63
5.27
9.45
10.8
Stock-based compensation
7.08
8.82
10.8
16.2
11.1
10.4
20.6
18.2
11.8
12.1
Change in inventory
-7.36
Cash from operations
-29.7
-48.2
-54.3
-104
-113
-53.6
10.7
-142
-141
-73.2
Capital expenditures
-5.08
-11.5
-24.6
-3.91
-1.59
-2.34
-8.57
-29.5
-4.68
-0.89
Purchases of investments
-153
-151
-27.3
-381
-140
-48.1
-76
-100
Sales and maturities of investments
29.1
138
125
105
224
167
211
44.1
Cash from investing
-58.8
17.8
-126
-17.5
94.9
-279
75.8
89.1
177
-59
Debt issued
49.5
Stock issued
0.02
103
99.7
0.37
334
2.53
12.8
0.62
29.2
Cash from financing
275
0.02
104
103
0.37
340
3.29
12.9
0.88
78.7
Exchange rate effect
-8.49
-5.58
2.33
3.34
-0.37
-0.96
0.37
-2.3
0.88
-0.4
Net change in cash
178
-36
-74.5
-15.8
-17.6
6.58
90.2
-42.1
37.4
-53.8
Free cash flow
-34.7
-59.7
-79
-108
-114
-55.9
2.16
-171
-146
-74.1
Interest paid
2.09
Income taxes paid
0.28
0.03
1.57
0.26
0.2
0.08
0.54
0.63
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2025; growth uses fiscal years. Valuation uses the share price of $0.02 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-252.3%
Operating income / revenue.
EBITDA margin
-237.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-255.1%
Pre-tax income / revenue.
Net margin
-260.8%
Net income / revenue.
FCF margin
-294.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-292.0%
Cash from operations / revenue.
Return on assets (ROA)
-129.9%
Net income / average total assets.
R&D / revenue
192.4%
Research and development expense / revenue.
SG&A / revenue
138.6%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
12.1%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.5%
Capital expenditures / revenue.
D&A / revenue
15.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
195.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
207.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
175.5%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-70.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-61.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-37.4%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-13.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-19.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
6.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
25.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
17.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
19.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.52x
Current assets / current liabilities.
Quick ratio
0.69x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.51x
(Cash + short-term investments) / current liabilities.
Debt / assets
19.7%
Total debt / total assets.
Liabilities / assets
154.3%
Total liabilities / total assets.
Net debt
-$386.0K
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.04
Revenue / diluted weighted shares.
FCF per share
-$0.12
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.12
Cash from operations / diluted weighted shares.
Book value per share
-$0.04
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.49x
Market cap / revenue.
EV/Sales
0.48x
Enterprise value / revenue.
FCF yield
-602.6%
Free cash flow / market cap.
Earnings yield
-533.7%
Net income / market cap (the inverse of P/E).
What was Adaptimmune Therapeutics PLC's revenue in fiscal 2024?
Adaptimmune Therapeutics PLC reported revenue of $178.0M for fiscal 2024, 195.3% higher than the year before.
Was Adaptimmune Therapeutics PLC profitable in fiscal 2024?
No. It reported a net loss of $70.8M.
How much free cash flow did Adaptimmune Therapeutics PLC generate in fiscal 2024?
Cash from operations of $73.2M minus capital expenditures of $886.0K left free cash flow of -$74.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.